A Phase 4 interventional study of sitagliptin phosphate in Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing sitagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. sitagliptin · Diabetes Mellitus.
Among the 58 studies testing sitagliptin in Diabetes Mellitus, this one is the 2nd largest by enrollment, is one of 11 that started in 2008, is one of 29 in phase 4, and was the 15th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 58 studies testing sitagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 12 · Phase 4 29
First in 2007; this study’s year is marked. 11 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 608 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 45 across the 58 interventional studies. Of the 54 that completed or were terminated, 28 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
15 studies in Diabetes Mellitus by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Diabetes Mellitus by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 4, and was the 2nd registered.
Merck & Co., Inc’s Diabetes Mellitus studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 58 studies testing sitagliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 15 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin
Inclusion Criteria:
Patient Is Currently On Monotherapy With Metformin For At Least 10 Weeks Prior To Study Entry
Sitagliptin
Drug: sitagliptin phosphate
Sitagliptin 100 mg/day - tablet for 24 weeks
Also known as: Januvia
Change From Baseline in HbA1c at Week 24
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent
Time frame: Baseline and Week 24
Change From Baseline in HbA1c at Week 12
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent
Time frame: Baseline and Week 12
First patient in: 11-MAR-2008 Last patient out: 30-OCT-2009 Total number of sites: 110
| Milestone | Sitagliptin 100mg |
|---|---|
| Started | 608 |
| Completed | 397 |
| Not completed | 211 |
| Withdrew: Adverse event | 33 |
| Withdrew: Death | 1 |
| Withdrew: Lack of efficacy | 12 |
| Withdrew: Lost to follow-up | 24 |
| Withdrew: Protocol violation | 115 |
| Withdrew: Withdrawal by subject | 16 |
| Withdrew: Missing | 10 |
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent
| Percent | Sitagliptin 100mg |
|---|---|
| Change From Baseline in HbA1c at Week 24 | -0.6 ± 0.95 |
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent
| Percent | Sitagliptin 100mg |
|---|---|
| Change From Baseline in HbA1c at Week 12 | -0.6 ± 0.85 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100mg | — | 17/608 (2.8%) | 0/608 (0%) |
| Event | Sitagliptin 100mg |
|---|---|
| Chest painGeneral disorders | 3/608 |
| DepressionPsychiatric disorders | 3/608 |
| Acute coronary syndromeCardiac disorders | 2/608 |
| Cardiac failure congestiveCardiac disorders | 1/608 |
| Cardiac tamponadeCardiac disorders | 1/608 |
| Myocardial infarctionCardiac disorders | 1/608 |
| GastritisGastrointestinal disorders | 1/608 |
| Inguinal hernia, obstructiveGastrointestinal disorders | 1/608 |
| Sudden deathGeneral disorders | 1/608 |
| GastroenteritisInfections and infestations | 1/608 |
| Age, Continuous(years) | Sitagliptin 100mg |
|---|---|
| Mean | 58.0 ± 11.23 |
| Sex: Female, Male(Participants) | Sitagliptin 100mg |
|---|---|
| Female | 258 |
| Male | 350 |
| Race/Ethnicity, Customized(participants) | Sitagliptin 100mg |
|---|---|
| Caucasian | 491 |
| Black | 16 |
| Hispanic | 6 |
| Asian | 73 |
| Native Indian | 6 |
| Other | 16 |
| Hemoglobin A1c (HbA1c)(percent) | Sitagliptin 100mg |
|---|---|
| Mean | 7.73 ± 1.11 |
| Weight(Kilograms) | Sitagliptin 100mg |
|---|---|
| Mean | 92.6 ± 24.42 |
| Fasting plasma glucose(mmol/L) | Sitagliptin 100mg |
|---|---|
| Mean | 9.3 ± 2.87 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
Ran from Mar 2008 to primary completion in Oct 2009, 19 months.
Results were first posted in Sep 2010, 10 months after primary completion.
Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 19 months is above that.
Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin